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The gut microbiome contributes 
to a substantial proportion of the 
variation in blood lipids
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Rationale: Evidence suggests the gut microbiome is involved in the development of 
cardiovascular disease (CVD), with the host-microbe interaction regulating immune and 
metabolic pathways. However, there was no firm evidence for associations between microbiota 
and metabolic risk factors for CVD from large-scale studies in humans. In particular, there was 
no strong evidence for association between CVD and aberrant blood lipid levels
Objectives: To identify intestinal bacteria taxa, whose proportions correlate with body mass 
index (BMI) and lipid levels, and to determine whether lipid variance can be explained by 
microbiota relative to age, gender and host genetics.
Methods and Results: We studied 893 subjects from the LifeLines-DEEP population cohort. 
After correcting for age and gender, we identified 34 bacterial taxa associated to BMI and 
blood lipids; most are novel associations. Cross-validation analysis revealed that microbiota 
explain 4.5% of the variance in BMI, 6% in triglycerides, and 4% in high-density lipoproteins 
(HDL), independent of age, gender and genetic risk factors. A novel risk model including 
the gut microbiome explained up to 25.9% of HDL variance, significantly outperforming the 
risk model without microbiome. Strikingly, the microbiome had little effect on low-density 
lipoproteins or total cholesterol.
Conclusions: Our studies suggest that the gut microbiome may play an important role in the 
variation in BMI and blood lipid levels, independent of age, gender and host genetics. Our 
findings support the potential of therapies altering the gut microbiome to control body mass, 
triglycerides and HDL.
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In recent years, the gut microbiome has emerged as an important player in human health.1,2 
Gut microbiota comprise thousands of microbial species that are involved in host metabolism 
by regulating energy extraction, activation of the immune system, drug metabolism and other 
processes.3,4 Association of bacterial composition to many diseases has been observed, 
including immune, inflammatory and metabolic phenotypes.5–7 Several mechanisms for 
the downstream effect of microbiota were discovered that also suggest they play a role in 
cardiovascular disease (CVD). The microbiota play an important role in choline diet-induced 
trimethylamine N-oxide (TMAO) production, which has been implicated in CVD.8 A further 
mouse study has demonstrated that atherosclerosis susceptibility can be transmitted via gut 
microbiota transplantation.9 Further, dysbiosis in the gut has been shown to induce increased 
permeability of the intestine, leading to increased systemic levels of bacterial products causing 
low-grade chronic inflammation.10 This inflammation may directly affect atherogenesis and 
has also been hypothesized to lead to the development of insulin resistance with concomitant 
effects on plasma lipids.11 Gut microbiota have also been linked with lipid metabolism through 
their role in bile acid metabolism. They can also influence the efficiency of energy harvest 
from ingested food12,13 and play a crucial role in the metabolic processes and development of 
obesity. 
In line with these observations, altering the gut microbiome in humans and mice has shown 
improvement in metabolic syndrome.14–16 However, the evidence for a causal relationship 
between the gut microbiome and the development of CVD has not been firmly established 
for lack of large-scale human studies. Atherosclerosis, a lipid-driven disease, is the main 
underlying cause of CVD. However, to date, no studies of sufficient size have been done 
to assess the association between lipids and microbiota. In this study, we performed a 
systematic analysis of host genome, gut microbiome, body mass index (BMI) and blood lipids 
Novelty and Significance
What Is Known?
• The human gut holds about 100 trillion bacteria, which together can weigh several pounds. 
• This ecosystem (the microbiome) is shaped by early life events, the host genome, diet and 
other lifestyle factors. 
• This bacterial community is associated with an individual’s susceptibility to many diseases, 
including cardiovascular diseases.
What New Information Does This Article Contribute?
• Healthy lipid levels are associated with increased microbial diversity.
• Body mass index (BMI) and blood lipids are associated with 34 different microbial 
taxonomies.
• A risk model including age, gender, genetic factors and gut microbiome explains a large 
part of the variation seen in BMI, triglycerides and high-density lipoprotein cholesterol.
The bacterial community in the human gut (known as the microbiome) has been referred to as an 
extra organ, or the second human genome, because of its important role in an individual’s health. 
As most of these bacteria cannot be cultured, we knew very little about their diversity and function 
until the recent development of innovative DNA sequencing technology. In our study we defined 
the microbial composition found in 893 human subjects by sequencing bacteria-specific 16s 
rRNA genes; we observed a large inter-individual variation in gut bacteria composition. We show 
that the bacterial diversity is associated with the lipid blood levels at human population level, 
especially with the levels of triglycerides and high-density lipoprotein cholesterol, and we report 
significant associations for 34 bacteria taxonomies. Our findings suggest microbial-intervention 





in 893 human subjects from the Dutch LifeLines-DEEP cohort.17 We investigated which gut 
bacteria were associated with BMI and blood lipids, and how much of the variation in blood 
lipids could be explained by the gut microbiome, relative to age, gender, body mass index and 
host genetics.
Results
Microbial Diversity in the LifeLines-DEEP Cohort
After quality control, our study included 893 human subjects. The study cohort had a wide 
range of age, BMI and blood lipids levels (Table 1). We assessed how variable the gut 
microbial composition was in the cohort in terms of microbial richness and diversity. The 
microbial richness reflects the number of OTUs per individual. The cohort had on average 238 
OTUs per individual, ranging from 44 to 355. When individuals were grouped into different 
bins based on their richness, we observed that age and the proportion of females were higher 
in the richer OTU groups (Figure 1). The Spearman correlation showed the richness was 
significantly higher in women (P=0.0055) and increased with age (P=5.87x10-12) (Online Table 
I). Given the abundance of OTUs, we computed the microbial diversity (Shannon’s diversity 
index) and observed similar significant correlations for age and gender (Online Table I). We 
then investigated whether bacterial richness and diversity were correlated with BMI and lipid 
levels. After correcting for age and gender, OTU richness was negatively correlated with BMI 
(P=3.8x10-4) and TG (P=1.37x10-4), but positively correlated with HDL (P=8.3x10-4). We did 
not observe significant correlations between microbial richness and LDL or TC levels (Online 
Table I).



























































Association of Bacteria to Lipid Metabolites
We next tested for association between the individual bacterial OTU, BMI and blood lipid 
levels. After adjusting for age and gender, we identified 148 associated OTUs at FDR=0.05: 
66 OTUs were associated with BMI, 114 with TG, and 34 with HDL (Online Tables II-IV). We 
did not detect any significant association at OTU level for LDL or TC. Of the 148 associated 
OTUs, 12 were shared by all three traits (BMI, TG and HDL); 29 OTUs were shared by BMI and 
TG and 4 by BMI and HDL, while 21, 64 and 9 OTUs were specifically associated with BMI, TG 
and HDL, respectively (Online Figure II). At the taxonomic level, we identified 50 significant 
associations for 34 unique taxonomies at FDR=0.05: 22 were associated with BMI, 23 with TG, 
4 with HDL, and 1 with LDL (Figure 2, Online Table V). We found 18 associations (36%) were 
detected by binary analysis (presence/absence); 4 associations (8%) were detected by the 
quantitative model; and 28 associations (56%) were detected by the meta-analysis of binary 
and quantitative analyses (Online Table V). Although most of the associated taxonomies were 
shared across lipid metabolites and BMI, several microbes were predominantly linked to lipids 
rather than BMI. For example, the family Clostridiaceae/Lachnospiracease (N16 in Figure 2), 
was specially associated with LDL (P=9.1x10-5) (Online Table V), and not detected for BMI, nor 
other lipids. Further, the family Pasteurellaceae (N32) (Proteobacteria), genus Coprococcus 
(N24) (Firmicutes) and genus Collinsella species Stercoris (N2) showed strong association to 
TG levels (P=6.2x10-5, P=4.6x10-5 and P=0.0006, respectively), a nominal significance to other 
lipids, and no association to BMI (P>0.1). 
We confirmed several previously described bacterial associations to obesity. An increased 
abundance of genus Akkermansia (N34) has been associated with a decrease in BMI 
(P=0.0005)18. We also confirmed the association of both the family Christensenellaceae 
(phylum Firmicutes) (N18) and the phylum Tenericutes (mainly represented by order RF-39) (N33) 
with low BMI (P=9.8x10-7 and P=0.0002, respectively), as reported in the TwinsUK cohort.19 In 
addition, we identified a novel and strong association of these particular bacteria with lower 
levels of TG (P=2.1x10-5 and P=2.7x10-7, respectively), and higher levels of HDL (P=0.0047 and 
P=0.0006, respectively). We also observed several new associations with BMI and levels of 
TG and HDL, such as genus Eggerthella (N3) with increased TG (P=4.1x10-5) and decreased 
HDL (P=6.3x10-5), and family Pasteurellaceae (N32) with decreased TG (P=6.2x10-5). The genus 
Butyricimonas (N9) was previously linked to a lean phenotype in mice after fecal transplantation 
from twins discordant for obesity.15 Our study shows that this genus is strongly associated 
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Figure 1. The richness of the gut 
microbiome. A. The microbial 
richness associated with age and 
gender. The bar plot shows the 
distribution of individuals binned 
to different groups of richness. The 
blue and red colors indicate the 
proportion of males and females in 
each group and the dark grey line 
indicates the correlation between 
the average age and richness, while 
the light grey shadow indicates the 






Variance of Blood Lipid Explained by Microbiota Composition
To anticipate how much BMI and blood lipids can be modulated by the gut microbiome, it is 
important to estimate what proportion of variation in these metabolic traits can be explained 
by the microbiome. To do so, we performed a 100x cross-validation analysis by splitting the 
dataset randomly into an 80% discovery set and a 20% validation set. The OTUs identified 
at P=1x10-5 level in the discovery set explained 2.74% variation in BMI in the validation set, 
3.83% in TG, 2.46% in HDL, 0.01% variation in LDL, and 0.01% in TC. When the association 
significance decreased and the risk model included more (but less-significant) OTUs, the 
explained variation increased to 4.57% in BMI, 6.0% in TG, 4.0% in HDL, but was only 1.5% in 
LDL and 0.7% in TC (Figure 3A). To test the robustness of our estimation, we re-rarefied the 
OTU library 100 times and repeated the whole analysis. This approach yielded similar results, 
thereby confirming the robustness of our estimation (Online Figure III). 
Microbiota Contribute Significantly to Lipid Variation, Independently of Age, 
Gender and Genetics
Evidence has already shown that the gut microbiome can be shaped by host genetics.19 
We further tested whether the explained variation in the gut microbiome was independent 
of genetic factors by testing the association between the gut microbiome and genetic risk 
scores.20 To date, 157 genetic loci have been reported to be associated with blood lipid levels21 
and 97 loci have been associated with BMI.22 In our cohort, these SNPs collectively explained 
2.1% variation in BMI (P=1.66x10-5), 3.4% in TG (P=3.22x10-8), 7.5% in HDL (P<2.2x10-16), 4.6% in 
LDL (P=8.0x10-11), and 5.6% in TC (P=7.7x10-13), after correcting for age and gender. However, 
we did not observe any significant association between the microbiome and the genetic risk 
at FDR=0.05. Nor did we find a significant association for either single SNPs (Online Table VI) 
or for the combined lipid and BMI genetic risk scores (Online Table VII). Our results indicated 
that the proportion of variation in BMI and lipid levels explained by the gut microbiome was 
different from that explained by genetic variation. Therefore, we further assessed whether 
1 .  k_Archaea 
2 .  s_Stercoris 
3 .  g_Eggerthella 
4 .  o_Bacteroidales 
5 .  f_Bacteroidaceae/Rikenellaceae
6 .  o__Bacteroidales: f_S24−7/Barnesiellaceae
7 .  g_Bacteroides 
8 .  f_Odoribacteraceae 
9 .  g_Butyricimonas 
10 .  g_Odoribacter 
11 .  f_Rikenellaceae 
12 .  o__Bacteroidales: f_S24−7 
13 .  p_Cyanobacteria 
14 .  o_Gemellales/Bacillales 
15 .  f_Mogibacteriaceae/Clostridiaceae/Lachnospiraceae 
16 .  f_Clostridiaceae/Lachnospiraceae 
17 .  f_Peptostreptococcaceae/Mogibacteriaceae/Clostridiaceae 
18 .  f_Christensenellaceae 
19 .  f_Clostridiaceae 
20 .  f__Clostridiaceae: g_02d06 
21 .  g_Dehalobacterium 
22 .  f_Lachnospiraceae 
23 .  g_Blautia 
24 .  g_Coprococcus 
25 .  g_Lachnospira 
26 .  f_Erysipelotrichaceae: g_CC_115
27 .  f_Erysipelotrichaceae: g_Holdemania 
28 .  o_Burkholderiales/Rhodocyclales 
29 .  f_Desulfovibrionaceae 
30 .  g_Bilophila 
31 .  c_Gammaproteobacteria 
32 .  f_Pasteurellaceae 
33 .  p_Tenericutes 
34 .  g_Akkermansia 
Z > 0, FDR < 0.05
Z > 0, FDR > 0.05
Z < 0, FDR < 0.05



















































































Figure 2. The effect of taxonomies on BMI and lipids. The effects of 34 taxonomies associated 
with BMI, TG and HDL are shown as Z-scores. Red sectors indicate positive associations and 
blue negative associations. Brighter colors indicate that the association was significant at FDR 





the microbiome could make a significant contribution to the explained variation beyond age, 
gender and genetic factors. Our analysis unambiguously showed that age, gender, genetics 
and the gut microbiome collectively explained 11.3% of the variation in BMI, 17.1% in TG 
and 25.9% in HDL-cholesterol, with the microbiome making a significant contribution to the 
explained variation in BMI (P=4.1x10-3), TG (P=4.5x10-4) and HDL (P=2.7x10-3) (Figure 3B). 
When we included BMI as a risk factor, the total explained variation in lipids increased to 
25% in TG, 37.4% in HDL, 22.3% in LDL, and 22.3% in TC (Online Figure IV). The microbiome 
made a lesser, but still significant, contribution to TG (P=4x10-3) and HDL (P=0.026). Our 
study therefore indicates that the gut microbiome can explain a substantial proportion of the 
variation, independent of age, gender, BMI and genetics.
Discussion
Obesity and aberrant levels of blood lipids are associated with a high risk of CVD. Studying the 
effect of the gut microbiome on BMI and blood lipid levels yields insight into the role of the 
microbiome in the development of CVD. Although animal studies have shown that microbiota 
can influence lipid metabolism,23 no large-scale studies have been performed in humans thus 
far. Here, we investigated the impact of the gut microbiome on BMI and blood lipid levels 
in 893 human subjects from the LifeLines-Deep cohort. The power of our study is reflected 
by three factors. First, to our knowledge, it is the largest association study linking the gut 
microbiome to blood lipids in humans to date. Second, our cohort represented a wide range of 
ages, BMI and blood lipids, as well as microbial composition. We also had detailed medication 
information per individual and could exclude those taking lipid-lowering or antibiotic 
medication. Moreover, we adopted a novel and powerful two-part model to account for both 
the binary and quantitative features of microbial data. We established associations for 34 
taxonomies with BMI and blood lipid levels, and we estimated that gut microbiota composition 
can explain up to 6% of the variation in lipid levels, and that this effect is independent of age, 
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Figure 3. The contribution of the gut microbiome to BMI and lipids. A. The variation explained 
by gut microbes at different levels of significance. B. The variation explained by different risk 
models including age, gender, genetic risk and microbial risk. The significance of microbial 
contribution is indicated as the P value of the ANOVA test that compared the performance of 





Our results for the microbiota associated to BMI are in line with a recent study of 416 twin-
pairs from the TwinsUK population19; in particular, we confirmed that lower abundances of 
families Christensenellaceae, Rikenellaceae, class Mollicutes, genus Dehalobacterium and 
kingdom Archaea were associated to a high BMI. Of 22 independent taxa associated with 
BMI by our study, 16 were also accessed in the TwinsUK study: 11 (68.8%) showed significant 
association to BMI (p<0.05) with the same direction of effect as we found (Online Table V). 
We also identified a correlation of decreased bacterial diversity with increased BMI, which is 
in line with previous observations.24
However, many of the taxonomies we identified are novel findings. Several of the identified 
bacteria are known to be involved in the bile acid metabolic pathway. In particular, order 
Bacteroidales (phylum Bacteroidetes) and family Clostridiaceae (phylum Firmicutes) are both 
negatively correlated with BMI and TG, and known to be involved in bile acid metabolism.25 
Bile acid activity of commensal bacteria are involved in a complex interplay with host hepatic 
enzymes, and together they promote digestion and absorption of dietary lipids.26 Interestingly, 
several small-scale studies reported lowered cholesterol upon using probiotics with bile 
salt hydrolytic activity.27,28 Our study found support for the role of bacterial bile acids in lipid 
metabolism. Another pathway enriched in several associated bacteria is short chain fatty 
acids (SCFA) metabolism. Both orders Bacteroidales and Clostridiales, identified in our study, 
are involved in SCFA metabolism.25 SCFA are produced by microbiota from dietary fibers, 
effect host body energy homeostasis, and are protective against metabolic syndrome, type 2 
diabetes, and atherosclerosis.16,29–31
To firmly establish the gut microbiome as a risk factor for obesity and aberrant levels of 
blood lipids, we have been able to estimate that the microbiome could explain 4.57-6% of 
the variation in BMI, TG and HDL, respectively. We did not detect any significant association 
between the gut microbiome and genetic predisposition to obesity and aberrant levels of 
blood lipids, suggesting the variation explained by the microbiome is independent of that 
explained by genetic variants. It should be noted, however, that the genetic risk score was 
limited to our established 157 lipid-associated SNPs21 and 97 BMI-associated SNPs22, which 
together only explain a small proportion of the heritability of lipid levels. We might have 
missed the effect of other, not yet discovered SNPs. Our risk model included age, gender, 
genetic variation, and gut microbiome and explained 11.3% of the variation in BMI, 17.1% in 
TG and 25.9% in HDL, significantly outperforming the risk model without the microbiome. 
Since blood lipids and BMI are highly correlated with each other and many associated bacteria 
were shared, we investigated whether the observed effect of the gut microbiome on lipids 
might just be the confounded effect of BMI. We showed that by including BMI in the risk 
model, the gut microbiome made a smaller, but significant, contribution to the variation in 
TG and HDL, suggesting that the microbiome affects blood lipids partly independently of 
BMI. Our results therefore indicate that the gut microbiome is a potentially important player 
in blood lipid metabolism. In contrast to genetics, gender and age (all fixed characteristics), 
an individual’s microbiota composition can be modified by diet, pre- and probiotics, and fecal 
transplantation. Studies have shown that diet can alter the gut microbiome.32 Our study has 
not addressed how much of the association we observed between gut microbiome and blood 
lipids might be explained by diet. A better understanding of this could provide more insights 
into the role of diet in microbiome and lipid metabolism. 
Our study supports the potential of microbiota-modifying intervention to correct lipid dis-
balance and thereby help prevent CVD. From potential to action, the next steps are to validate 
the associations we report in independent cohorts and to prove there is a causal axis of gut 
microbiome-lipids-CVD in functional studies. It is essential to gain more mechanistic insight 
into the functioning of the gut microbiome, although research in humans is still in its infancy. 
The gut microbiomes in our study were profiled by 16s rRNA gene sequencing. This technology 
can identify microbial taxonomies and composition, but has limitations in identifying 





information on bacterial genes and their functions. With the decreasing cost of metagenome 
sequencing and development of techniques for culturing and for functional studies of gut 
bacteria, we expect to learn more about the levels of bacterial genes, metabolic pathways and 
their functions in the future.
In conclusion, we have observed a strong association between the gut microbial composition 
and the variation in BMI and blood lipid levels, which is independent of age, gender and 
host genetics. This observation provides insight into the microbiome’s role in regulating 
metabolic processes during the development of CVD. We established associations for a total 
of 34 intestinal bacteria taxonomies with BMI and blood lipids. We observed that the gut 
microbiome makes a significant contribution, beyond that of clinical risk factors and genetics, 
to the individual variance seen in BMI and to the blood levels of triglycerides and HDL, but 
that it has little effect on LDL or total cholesterol levels. Our results highlight the potential of 
therapies that alter the gut microbiome to control body mass, triglycerides and HDL in CVD 
prevention. In moving from potential to action, it will be essential to identify the causal axis of 
microbiome-lipids-CVD and to gain more mechanistic insight into the gut bacteria functions.
Methods
Population Cohort
The LifeLines-DEEP cohort is a sub-cohort of the LifeLines cohort (167,729 subjects),33 
which employs a broad range of investigative procedures in assessing the biomedical, socio-
demographic, behavioral, physical and psychological factors that contribute to the health and 
disease of the general population. A subset of approximately 1,500 participants also took 
part in LifeLines-DEEP: for these participants, additional biological materials were collected, 
including genome-wide genotyping and analysis of the gut microbiome composition. A full 
description of the LifeLines-DEEP dataset is given in the paper describing the study design.17
Lipid Measurements
We had lipid measurements available for all 1,500 LifeLines-DEEP samples. Total cholesterol 
(TC) was measured with an enzymatic colorimetric method, high-density lipoprotein (HDL) 
cholesterol with a colorimetric method, and triglycerides (TG) with a colorimetric UV method 
(Modular P analyzer, Roche Diagnostics, Burgdorf, Switzerland). The low-density lipoprotein 
(LDL) cholesterol concentration was calculated using the Friedewald equation. More details 
were reported previously.34 The triglyceride level was further log2 transformed.
Genotype Information
All LifeLines-DEEP samples were genotyped using the HumanCytoSNP-12 BeadChip and 
ImmunoChip, a customized Illumina Infinium array. The data were harmonized,35 merged 
and subsequently imputed using the Genome of the Netherlands (GoNL) dataset.36,37 Further 
details and information on the quality control are described in Tigchelaar et al.17 We removed 
ethnic outliers and genetically related participants from our study.
Microbiome Data Generation
Sequencing
Microbiome data was generated for 1,180 LifeLines-DEEP samples. Fecal samples were 
collected at home within two weeks after collection of blood samples, and stored immediately 
at -20 oC. After transport on dry ice, all samples were stored at -80 oC. Aliquots were made and 
DNA was isolated with the AllPrep DNA/RNA Mini Kit (Qiagen; cat. #80204). Isolated DNA was 
sequenced at the Broad Institute, Boston, using Illumina MiSeq paired-ends. Hyper-variable 
region V4 was selected using forward primer 515F [GTGCCAGCMGCCGCGGTAA] and reverse 
primer 806R [GGACTACHVGGGTWTCTAAT]. We used custom scripts to remove the primer 






Selection of unique bacterial sequences so-called operational taxonomic unit (OTU) picking 
was performed using the QIIME reference optimal picking, which uses UCLUST39 (version 
1.2.22q) to perform the clustering. Matching OTUs to bacteria was done using a primer-specific 
version of the GreenGenes 13.5 reference database.40 Using TaxMan,41 we created the primer-
specific reference database containing only reference entries that matched the selected 
primers. During this process we restricted probe-reference mismatches to a maximum of 
25%. The 16S regions that were captured by our primers, including the primer sequences, were 
extracted from the full 16S sequences. For each of the reference sequences, we determined 
the overlapping part of the taxonomy of each of the reference reads in the clusters and used 
this overlap as the taxonomic label for the cluster. This process is based on, and similar to, 
work described in Bonder et al.,42 Brandt et al.,41 May et al.43 and Ding et al.44 We used QIIME45 
for exploratory analysis and for gathering basic statistics on the microbiome dataset.
Quality Control
Overall, for 1,021 samples, we had lipid measurements, genotype and microbiome information. 
We excluded 99 samples from participants who were taking antibiotic or other potential 
microbiome-modifying drugs, or who were on lipid-lowering medication. The library size of 
microbial sequencing varied greatly among samples, ranging from 3,969 to 336,900 reads. The 
sequence depth can significantly bias the measures of microbial composition and rarefication 
was widely used to make the library sizes equal by randomly selecting the same number of 
reads per sample.46,47 We compared the number of samples at different sequence depths and 
determined the rarefication depth based on criteria to obtain both the number of reads and 
the number of samples as high as possible. We rarefied the library size to 15,000 read-depth 
using the rarefy function in R package vegan (v2.3-0). At this depth, we only excluded 29 
subjects. After these exclusion steps, we had 893 samples (380 males and 513 females) for 
final analysis. Their characteristics are summarized in Table 1.
Further, we filtered on the OTU abundance and confined our analysis to 645 OTUs, each of 
which comprised ≥0.05% of reads and was present in at least 1% of the population. These 
OTUs accounted for an average of 99% of total reads per sample. The OTUs were assigned 
to 173 taxonomies that were further truncated to 136 taxonomies after removing identical or 
highly similar information between different clade levels. 
Statistical Analysis
Analysis of microbial diversity
The microbial Shannon diversity index was calculated using the diversity function in R package 
vegan (version 2.3-0).
Two-part model for association analysis
We observed that the distribution of the abundance of OTUs or taxonomies departed 
significantly from a normal distribution due to the fact that bacteria were not presented in 
many samples. Only 50 out of 645 OTUs (7.7%) were presented in more than 90% of samples, 
whereas 448 OTUs (69.5%) were detected in less than 50% of samples. At the taxonomic 
level, 32 out of 136 (9.5%) taxonomies were detected in more than 90% of samples, whereas 
60 taxonomies (44.1%) were detected in less than 50% of samples. There are different 
explanations for the detection rate: (1) the bacteria are really absent in the samples; (2) the 
abundance levels of bacteria are lower and not to be detected at the current sequencing and 
rarefication depth; (3) the abundance levels are similar and it is a random effect due to the 
sequencing or rarefication procedure. We therefore adopted a novel, two-part model that 
was developed to account for both binary (detected/undetected) and quantitative features.48 
This approach overcomes the problem of a non-normal distribution, which is a feature of the 





The two-part model is illustrated in Online Figure I. The first part describes a binomial analysis 
that tests for association of detecting a microbe (represented by an OTU or a taxonomy) with 
a trait. The binary feature (b) of a microbe under study was coded as 0 for undetected or 1 
for detected for each sample. The binary model is described as: y = b1b+ e , where y refers to 
the trait level (BMI or lipid level) per individual after adjusting for age and gender; b is a binary 
feature; b1is the estimated effect for the binary effect, and e represents the residuals.
The second part of the quantitative analysis tests for association between the lipid level 
and the abundance of bacteria, but only for the subjects where that microbe is present. The 
abundance level (q) of a microbe was the log10 transformed read count per individual. The 
quantitative model is written as y = b2q+ e ; where q is the abundance of a microbe; b2 is the 
estimated effect for the abundance, and e represents the residuals.
To further combine the effect of both binary and quantitative analysis, a meta-P-value was 
derived using an unweighted Z method. Then a final association P value per microbe-trait pair 
was assigned from the minimum of P values from the binary analysis, quantitative analysis 
and meta-analysis. The association Z-score was calculated based on the Z-distribution. If 
the association direction was negative, the Z-score was assigned a negative value. If the 
association direction is positive, the Z-score was assigned a positive value.
The association P value was set as the minimum value of three P values and the distribution 
of the association P values could be skewed, so we therefore performed 1000x permutation 
tests to control the false discovery rate (FDR). For each permutation, we randomized the gut 
microbial composition across individuals and performed the two-part analysis on permuted 
data. At a certain P cut-off, the average number of the detected significance (N0) in 1000x 
permutations was defined as the false positive, and its ratio to the detected positive (N1) in the 
real analysis was the FDR. We controlled the FDR at 0.05.
This method accounts for the complicated features of the microbial data and maximizes the 
power. If the association P value comes from the binary model, indicating the effect is only 
due to the presence/absence of the microbe, the abundance of the microbe in the samples 
does not matter. If the association P value comes from the quantitative model, this indicates 
the abundance level of the microbe associates with the trait, and the absence of the microbe 
has no influence. The explanation would be another microbe takes its place and has a similar 
function. If the association P value comes from the meta-analysis, indicates that both the 
presence/absence and the abundance of microbes can influence the trait. 
Estimating the Variance Explained by the Gut Microbiome
To estimate the proportion of variation in BMI and lipids that could be explained by the gut 
microbiome, we performed a 100x cross-validation. Each time we split the data randomly into 
an 80% discovery set and a 20% validation set. In the discovery set, a total of n number of 
significantly associated OTUs was identified at a certain P value and the effect sizes of binary 
and quantitative features of each OTU ( b1and b2 ) were estimated. Then the risk of the gut 
microbiome on BMI or lipids (rm) for each individual in the validation set was calculated using 
an additive model: 
r b qj j j
j
n
m = + +
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The variation in BMI and blood lipids explained by the gut microbiome was represented as 
the squared correlation coefficient (R2) between the traits and rm, after correcting for age and 
gender. To ensure the robustness of our estimation, we repeated the cross-validation 100 
times and calculated the average value of the explained variation. We hypothesized that many 
microbes may contribute a small effect but may not be confidently detected at an FDR of 0.05. 
Therefore, we did this analysis at different significant P levels ranging from 1x10-5 to 0.1.
Genetic Risk Score Calculation
A total of 157 lipid-associated single nucleotide polymorphisms (SNPs)21 and 97 BMI-
associated SNPs22 were extracted from the literature. The risk alleles and their effect 
sizes were extracted for each SNP and each lipid type. We excluded three SNPs for which 
genotypes could not be successfully imputed in the LifeLines cohort: rs9411489 at the ABO 
locus, rs3177928 at the HLA locus, and rs12016871 at the MTIF3 locus. Thus, our final study 
included genetic information for 96 BMI-associated SNPs and 155 lipid-associated SNPs, 
including 71for HDL, 56 for LDL, 40 for TG and 72 for TC. We then computed weighted genetic 
risk scores (rg) for BMI and lipids, as described previously.
34
The association analysis between individual SNPs and the gut microbiome was performed 
using the analysis pipeline developed in house for quantitative trait loci analysis.49 We further 
tested whether the explained variation in the gut microbiome was independent of genetic 
factors by testing the association between the gut microbiome and genetic risk scores. 20 
The associations between microbes and the genetic risk score of BMI and lipid levels were 
assessed using our two-part model. The significance was controlled at FDR<0.05 by 1000x 
permutation tests.
The Significance of the Microbial Contribution
To test whether the gut microbiome contributes significantly to variation in BMI and blood 
lipids, we compared the performance of three different risk models, in particular the risk 
models with and without microbial risk: 
r1 = age+ gender ;
r2 = age+ gender + rg ; and
r3 = age+ gender + rg + rm , 
where rg is the calculated genetic risk and rm is the highest microbial risk we determined. The 
variation explained by each risk model was calculated in 100x cross-validation, as described 
above. To evaluate the significance of microbial contribution, the ANOVA test was used to 
compare the performance of the risk models r3 and r2: the average of F values of the ANOVA 
test from 100x cross-validation was calculated and the P value was determined based on the 
F-distribution. As BMI and lipids are highly correlated, we also investigated whether the gut 
microbiome can contribute to lipid levels independent of BMI. To do so, we tested four risk 
models of lipids including BMI as a risk factor: 
r1 = age+ gender ; 
r2 = age+ gender + bmi ; 
r3 = age+ gender + bmi+ rg ; and 
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